Opthea Limited (OPT)
Market Cap | 229.96M |
Revenue (ttm) | 138,198 |
Net Income (ttm) | -64.46M |
Shares Out | 58.36M |
EPS (ttm) | -1.47 |
PE Ratio | n/a |
Forward PE | 6.73 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,952 |
Open | 3.91 |
Previous Close | 3.93 |
Day's Range | 3.91 - 3.96 |
52-Week Range | 3.91 - 8.50 |
Beta | 0.31 |
Analysts | Buy |
Price Target | 9.16 (+132.49%) |
Earnings Date | n/a |
About OPT
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ... [Read more]
Financial Performance
In 2022, Opthea's revenue was 199,005, an increase of 108.24% compared to the previous year's 95,563. Losses were -92.82 million, 104.7% more than in 2021.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for OPT stock is "Buy." The 12-month stock price forecast is $9.16, which is an increase of 132.49% from the latest price.
News

Opthea Receives A$8.7 million R&D Tax Incentive
MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

Opthea To Participate in Fireside Chat at Oppenheimer's 33rd Annual Healthcare Conference
MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea To Present at SVB Leerink Global Biopharma Conference
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea To Present at Sequire Biotechnology Conference
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea to Present at the FLORetina 2022 Congress
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea to Present at Jefferies London Healthcare Conference
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
Secured up to US$170m in non-dilutive financing

Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Successfully Closes Well Supported US$90 Million Equity Financing
MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent ...

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
MELBOURNE, Australia and BOSTON, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX: OPT; NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevale...

Opthea To Present at Upcoming Investor Conferences
MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...

Opthea Presentation at The Retina World Congress 2022
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022
MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

Opthea strengthens its Board of Directors
Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmo...

Opthea To Present at Oppenheimer's 32nd Annual Healthcare Conference
MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retin...

Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer
MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...

Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The data presented was a prespecified subgroup a...

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea's Phase 2b clinical trial of OPT-302 in combination with ranibizum...

Opthea To Present at SVB Leerink Global Healthcare Conference
MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...

Opthea Receives A$6.6 m R&D Tax Incentive
MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...